Published by Josh White on 14th November 2022
(Sharecast News) - Hutchmed China announced initial results from the 'FRUTIGA' phase 3 study of fruquintinib combined with paclitaxel in 703 Chinese patients with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma on Monday.
URL: http://www.digitallook.com/dl/news/story/33105610/...